– Treatment with linsitinib in a clinically relevant mouse model demonstrated a significant reduction in autoimmune response and classical Thyroid Eye Disease (TED) symptoms, independent of TED severity – – Ongoing global Phase 2b LIDS clinical trial evaluating linsitinib for treatment of…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.